Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is slated to received unconditional EU antitrust approval for its proposed $16.5B acquisition of Catalent (CTLT), Reuters’ Foo Yun Chee and Maggie Fick report, citing a person with direct knowledge of the matter. Another source told Reuters that Catalent is preparing senior management for the takeover to go through.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter